AEON Biopharma, Inc.

AEON Biopharma, Inc. (Nasdaq: AEON) is a biopharmaceutical company that became publicly traded through a de-SPAC merger with Priveterra Acquisition Corp., a blank-check vehicle sponsored by Priveterra Sponsor LLC that completed its IPO in 2022. The transaction closed in 2023, bringing AEON into the public markets with a focus on developing botulinum toxin therapeutics for both therapeutic and aesthetic indications. The company filed an 8-K with the SEC on June 17, 2026, reflecting continued post-merger reporting obligations as an active public issuer in the life sciences sector. Investors and analysts tracking AEON and other SPAC-originated biotech names can sign up at SpacDesk for full filing histories, sponsor profiles, and deal-level analytics.